G-Protein Coupled Receptor 160 Inhibition Prevents the Development of Oxaliplatin-Induced Neuropathic Pain and Alteration of Perineuronal Net in the Spinal Cord of Rats

Peripheral neuropathy accompanied by a treatment resistant neuropathic pain syndrome is a major dose-limiting toxicity of platinum-based chemotherapeutics used to treat colorectal cancer, such as oxaliplatin. Our recent studies linked GPR160 in the spinal cord to the development of pain. However, little is known of the role of GPR160 in chemotherapy-induced neuropathic pain syndromes. Here, we tested whether GPR160 in the spinal cord contributes to the development of hypersensitivities and central sensitization in a rat model of oxaliplatin-induced neuropathic pain.
Source: The Journal of Pain - Category: Materials Science Authors: Source Type: research